Ozempic and Blindness: What We Know About Weight Loss Side Effects
Administered as a once-weekly subcutaneous injection, Ozempic not only helps control blood glucose levels but also reduces ...
Novo Nordisk CEO: side-effects not a problem in CagriSema study
Novo Nordisk's CEO said on Wednesday side-effects were not a problem in the trial of its next-generation obesity drug ...
Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Josh Gad reveals he had to stop taking weight-loss drug due to side effects: ‘Really bummed out’
The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...
Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...
MedCity News7d
Oral Metabolic Drug Acquired by Novo Nordisk Continues to Show Concerning Neuro Side Effects
Last September, Novo Nordisk reported Phase 2 obesity study results showing statistically significant weight loss at 16 weeks across all three doses tested. While gastrointestinal side effects ...
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
WDRB1d
The 2 sides of Ozempic — weight loss success stories and health nightmares in Kentucky
The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...
FierceBiotech6d
Novo flunks kidney disease trial, again linking obesity prospect to neuropsychiatric side effects
Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. | Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. Months after sharing obesity data that ...
Yahoo Finance6d
Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results
That silence is even louder coming from Novo Nordisk ... of 22.7% of their original weight, below the targeted 25% weight loss, and came with challenging side effects. The company has lost ...